Pharmaceutical On a positive news day for AstraZeneca, the stock gained 1.1%, hitting £73.53 this morning, after the company announced positive results from a late-stage trial on its triple combo drug Breztri Aerosphere and that the US Food and Drug Administration has granted Orphan Drug designation to Fasenra (benralizumab), for the treatment of eosinophilic esophagitis (EoE). 28 August 2019